Risk Of Developing Liver Cancer After HCV Treatment

Wednesday, August 24, 2016

August - Recruiting and upcoming hepatitis C clinical trials

August - Recruiting and upcoming hepatitis C clinical trials 

This is not a complete list of HCV clinical trials, to find out if a study is enrolling patients in your area please click here, or here for hepatitis trials listed by state.

Learn more about drugs used to treat hepatitis C by viewing the following links;

I highly suggest you begin with this incredible new blog recently launched by HCV Advocate; HCV Medications Blog. The blog is easy to navigate with treatment information listed clearly by HCV genotype. ​In addition each month HCV Advocate puts out a newsletter with helpful articles about living with or treating the virus. An overview of approved drugs or agents still under investigation is offered as well.

Hepatitis C Cures: New Drugs and Treatment Discussed
Hepatitis C can now be cured. There are new FDA approved medicines to treat hepatitis C with over a 95% cure rate. Dr. Joseph Galati with Liver Specialists of Texas discusses the new drugs including Epclusa, Zepatier, Harvoni, Sovaldi, Viekira Pak, and Olysio.

News Updates - Epclusa
Gilead's Epclusa®  FDA approved June 28,2016 is a once-daily, fixed-dose combination of Sovaldi with velpatasvir (GS-5816) a pangenotypic NS5A inhibitor, for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection.

Category: Epclusa

Approved Treatments for Hepatitis C

Treating HCV According To Genotype

August - Recruiting and upcoming hepatitis C clinical trials

Spain
This study is currently recruiting participants
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis
Please refer to this study by its ClinicalTrials.gov identifier: NCT02781558
Contacts - Locations
Contact: Gilead Study Team 342-2097alerts@gilead.com
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL; Drug: RBV

Find Out More

Maryland
This study is currently recruiting participants
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Subjects With Previous DAA Experience
Please refer to this study by its ClinicalTrials.gov identifier: NCT02745535
Condition: Chronic Hepatitis C
Intervention: Drug: Sofosbuvir/Velpatasvir/GS-9857
Contacts
Contact: Eleanor Wilson, MD 410-706-1710 ewilson@ihv.umaryland.edu
Contact: Jennifer Hoffmann, MSN/MPH 410-706-0294 jhoffmann@som.umaryland.edu 
Locations
United States, Maryland
Institute of Human Virology Recruiting
Baltimore, Maryland, United States, 21201

This study is not yet open for participant recruitment
Please refer to this study by its ClinicalTrials.gov identifier: NCT02783976
Contacts - Locations
Contact: 334-1685 Gilead Study Team GS-US-334-1685@gilead.com
Condition: HCV Infection Intervention: Drug: SOF Sponsor: Gilead Sciences
verified May 2016 (Source: ClinicalTrials.gov)
May 24, 2016

This study is currently recruiting participants
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
Please refer to this study by its ClinicalTrials.gov identifier: NCT02781571
Contacts - Locations
Contact: Gilead Study Team 342-2104alerts@gilead.com
Condition: Hepatitis C Virus Infection Intervention: Drug: SOF/VEL Sponsor: Gilead Sciences

Some locations are open for participant recruitment
Please refer to this study by its ClinicalTrials.gov identifier: NCT02786537
Contacts
Contact: Gilead Study Team 342-2104alerts@gilead.com  
Condition: Chronic Hepatitis C Interventions
Drug: sofosbuvir/ledipasvir; Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir; Drug: elbasvir/grazoprevir
Sponsors: University of North Carolina, Chapel Hill; Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme Corp.; AbbVie - verified May 2016 (Source: ClinicalTrials.gov)

Locations
United States, Arkansas
Liver Wellness Center
Not yet recruiting
Little Rock, Arkansas, United States, 72205
Contact: Lynn Frazier, ARNP    501-687-9300    LFRAZIER@ADCLR.COM   
Principal Investigator: Alonzo Williams, MD         
United States, California
UCSD Medical Center
Not yet recruiting
San Diego, California, United States, 92103
Contact: Sharon Quigley    858-657-5147    sjquigley@ucsd.edu   
Principal Investigator: Alexander Kuo, MD         
UCSF/San Fran General Hospital
Not yet recruiting
San Francisco, California, United States, 94110
Contact: Yu-Chi Lapid       Yu-Chi.Lapid@ucsf.edu   
Principal Investigator: Mandana Khalili, MD         
Univ of California, San Francisco
Recruiting
San Francisco, California, United States, 94143
Contact: Daisy Rios    415-476-8063    daisy.rios@ucsf.edu   
Principal Investigator: Nora Terrault, MD         
United States, Connecticut
Yale University Digestive Diseases
Recruiting
New Haven, Connecticut, United States, 06520
Contact: Claudia Bertuccio    203-785-2204      
Principal Investigator: Joseph Lim, MD         
United States, District of Columbia
Georgetown University
Recruiting
Washington, District of Columbia, United States, 20007
Contact: Erica Christian       erica.christian@gunet.georgetown.edu   
Principal Investigator: Coleman Smith, MD         
United States, Florida
University of Florida
Recruiting
Gainesville, Florida, United States, 32610-0272
Contact: Patrick Horne, ARNP    352-273-9500    PATRICK.HORNE@MEDICINE.UFL.EDU   
Contact: Briana Foerman, BS    352-294-5152    briana.foerman@medicine.ufl.edu   
Principal Investigator: Giuseppe Morelli, M.D.         
University of Florida, Jacksonville
Recruiting
Jacksonville, Florida, United States, 32209
Contact: Kelly Jackman, PHD    904-633-0070    kelly.jackman@jax.ufl.edu   
Principal Investigator: Miguel Malespin, MD         
University of Miami/Schiff Center for Liver Diseases
Recruiting
Miami, Florida, United States, 33136
Contact: Eva Pavicic       epavicic@med.miami.edu   
Contact: Maria Onate-Silva       mlourdeso@med.miami.edu   
Principal Investigator: Eugene Schiff         
Orlando Immunology Center
Recruiting
Orlando, Florida, United States, 32803
Contact: Jeff Dinsmore    407-409-7125    jdinsmore@oicorlando.com   
Principal Investigator: Federico Hinestrosa, MD         
United States, Georgia
Internal Medicine Associates of Wellstar Atlanta Medical Center
Recruiting
Atlanta, Georgia, United States, 30312
Contact: Howard Brown    404-265-4194    dyardmon3@gmail.com   
Principal Investigator: Brian Pearlman, MD         
United States, Illinois
Northwestern University
Not yet recruiting
Chicago, Illinois, United States, 60611
Contact: Sara Lescano    312-694-0243    sara.lake@northwestern.edu   
Principal Investigator: Josh Levitsky, MD         
United States, Indiana
Indiana University Medical Center
Not yet recruiting
Indianapolis, Indiana, United States, 46202
Contact: Martha Mendez, RN    317-278-4633    mwmendez@iupui.edu   
Principal Investigator: Paul Kwo, MD         
United States, Maryland
John Hopkins University
Recruiting
Lutherville, Maryland, United States, 21093
Contact: Stephanie Katz, MSN,RN    443-287-9605    SSNEDDO2@JHMI.EDU   
Contact: Stacey Reese    410-955-9944    SREESE2@JHMI.EDU   
Sub-Investigator: Mark Sulkowski, MD         
Principal Investigator: Juhi Moon, MD         
United States, Michigan
University of Michigan
Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Diane White, CCRP    734-763-6647    dfwhite@umich.edu   
Principal Investigator: Anna SF Lok, MD         
United States, Minnesota
University of Minnesota
Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Stacy Valenzuela    612-624-9926      
Principal Investigator: Mohamed Hassan, MD         
United States, Missouri
Saint Louis University
Recruiting
Saint Louis, Missouri, United States, 63104
Contact: Kristina L Wriston, RN    314-977-9400    KWRISTON@SLU.EDU   
Contact: Caroline Vemulapalli-Forrest       cvemulap@slu.edu   
Principal Investigator: Adrian DiBisceglie, MD         
United States, Nebraska
University of Nebraska Medical Ctr
Recruiting
Omaha, Nebraska, United States, 68198
Contact: Beth Kos, BSN    402-559-3652    MEKOS@UNMC.EDU   
Principal Investigator: Mark Mailliard, MD         
United States, New Mexico
Southwest CARE Center
Recruiting
Santa Fe, New Mexico, United States, 87505
Contact: Joanna Pierce       jpierce@southwestcare.org   
Contact: Christopher Gallegos       cgallegos@southwestcare.org   
Principal Investigator: Joel N Gallant, MD         
United States, New York
Weill Cornell Medical College
Recruiting
New York, New York, United States, 10021
Contact: Marlene Feron-Rigodon, RN    646-962-2085    maf2062@med.cornell.edu   
Principal Investigator: Robert Brown, MD         
Columbia University Medical Center
Recruiting
New York, New York, United States, 10032
Contact: Jennie Chavis    212-305-3839    jc4380@cumc.columbia.edu   
Principal Investigator: Elizabeth Verna, MD         
Mountain View Medical Center
Recruiting
Valatie, New York, United States, 12184
Contact: Ananth Ramani    518-943-1943    ramani489@yahoo.com   
Principal Investigator: Anathakrishnan Ramani, MD         
United States, North Carolina
University of North Carolina at Chapel Hill
Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Tiffany Pritchett, B.A.       tpritch@med.unc.edu   
Contact: Renee Blanchard    919-843-5936    renee_blanchard@med.unc.edu   
Principal Investigator: Michael W. Fried, M.D         
Duke University Medical Center
Recruiting
Durham, North Carolina, United States, 27710
Contact: Loranda Ross    919-681-2941    loranda.ross@duke.edu   
Principal Investigator: Andrew Muir, MD         
United States, Ohio
University of Cincinnati
Recruiting
Cincinnati, Ohio, United States, 45267
Contact: Liz Stambrook, BSN    513-584-2363    LIZ.STAMBROOK@UCHEALTH.COM   
Contact: Diane Daria       dariade@ucmail.uc.edu   
Principal Investigator: Kenneth Sherman, MD         
United States, Pennsylvania
University of Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Kelly Borges    215-615-3755    kelly.borges@uphs.upenn.edu   
Principal Investigator: Rajender Reddy, MD         
United States, Texas
Research Specialist of Texas
Recruiting
Houston, Texas, United States, 77030
Contact: Christina McNeil    713-634-5110    cmcneil@texasliver.com   
Contact: Wilma Regalado       wregalado@texasliver.com   
Principal Investigator: Joseph Galati, MD         
United States, Virginia
Bon Secours St. Mary 's Hospital of Richmond (Liver Institute of Virginia)
Recruiting
Richmond, Virginia, United States, 23226
Contact: Susan Vollum, RN, CRC    804-977-8921    susan_vollum@bshsi.org   
Principal Investigator: Mitchell L. Shiffman, MD         

Please refer to this study by its ClinicalTrials.gov identifier: NCT02581189
Contacts
Contact: Nabil Ackad, MD 514-832-7439 nabil.ackad@abbvie.com
Contact: Catherine Pinsonnault, BS 514-832-7015 catherine.pinsonnault@abbvie.com
Locations
Canada

Condition: Chronic Hepatitis C
Intervention:

Japan
This study is currently recruiting participants
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
Please refer to this study by its ClinicalTrials.gov identifier: NCT02671500
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Locations
Malaysia

University of Malaya Recruiting
Kuala Lumpur, Malaysia, 59100
Hospital Tengku Ampuan Afzan Recruiting
Pahang, Malaysia, 25100
Singapore
National University Hospital Recruiting
Singapore, Singapore, 119074
Singapore General Hospital Recruiting
Singapore, Singapore, 169608

This study is currently recruiting participants
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
Please refer to this study by its ClinicalTrials.gov identifier: NCT02738333
Locations -  Japan
Contacts
Contact: Gilead Study Team GS-US-337-1903@gilead.com
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF; Drug: SOF; Drug: RBV  

This study is currently recruiting participants
Please refer to this study by its ClinicalTrials.gov identifier: NCT02615145
Locations
Germany
Condition: Chronic Hepatitis C

This study is currently recruiting participants
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS
Please refer to this study by its ClinicalTrials.gov identifier: NCT02636608
Locations
Hungary
Condition: Chronic Hepatitis C

This study is currently recruiting participants
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study
Please refer to this study by its ClinicalTrials.gov identifier: NCT02798315
Locations
Kuwait
Condition: Chronic Hepatitis C

This study is currently recruiting participants
The Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in France
Please refer to this study by its ClinicalTrials.gov identifier: NCT02618928
Locations
France
Condition: Chronic Hepatitis C

No comments:

Post a Comment